What could you do if your data was working for you and not against you? With Bloomberg delivering

enterprise data directly to your systems, you get easy access to the details you want, optimized for

higher level analysis, and financial data experts committed to helping you maximize your every move.

Our data is made for more, so you can show the world what you're made of.

Visit Bloomberg.com slash enterprise data to learn more.

Millions of Americans take prescription drugs, but how many of us really know how they were developed, or how they even work?

For most of us, drugs are just there. When you pick up your prescription from the pharmacy, you don't think about the billions of dollars that went into the research, or the scientific breakthroughs that paved the way.

Welcome to Prognosis, a podcast about health, medical technology, and the mind-blowing

innovation that's underway across the globe. I'm your host, Michelle Faye Cortez.

This week we're hearing the story of the strange circuitous path of one drug from the Eureka

moment to the market.

It's a story about a Nobel Prize winner, cutting-edge genetic research, billions of pharmaceutical

dollars, and of all things, a worm. In August, Alnilum, a $7 billion biotechnology company won approval to market its first drug.

The company hopes it will save the lives of roughly 50,000 patients who suffer from a rare

and ultimately fatal disorder.

But the price sounds outrageous.

Each patient, or rather the federal government and their insurance companies,

will have to pay about $345,000 every year.

Here's Rebecca Spalding, Bloomberg's Boston Biotech reporter,

on the 16-year journey of a single drug.

I'm here in Cambridge, Massachusetts, the global capital of the drug industry. As a pharmaceutical executive told me recently what New York is to finance and Paris is to culture, Cambridge is to science.

Its heart is a place called Kendall Square next to MIT.

...